Synlogic - Stock Price History | SYBX

Historical daily share price chart and data for Synlogic since 2021 adjusted for splits. The latest closing stock price for Synlogic as of September 24, 2021 is 3.17.
  • The all-time high Synlogic stock closing price was 65.99 on December 17, 2015.
  • The Synlogic 52-week high stock price is 5.11, which is 61.2% above the current share price.
  • The Synlogic 52-week low stock price is 1.78, which is 43.8% below the current share price.
  • The average Synlogic stock price for the last 52 weeks is 3.15.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Synlogic Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.2017 2.6800 3.1950 1.3900 2.1600 -16.28%
2019 5.8055 7.6200 10.2400 1.9600 2.5800 -63.20%
2018 10.0968 10.8000 14.4900 5.9500 7.0100 -27.73%
2017 13.4404 12.5962 21.7900 9.1500 9.7000 -22.99%
2016 24.5458 43.4570 43.5969 8.0476 12.5962 -71.20%
2015 44.1579 49.3352 65.9902 39.6081 43.7369 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.167B $0.001B
Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71